(CIDRAP News) For the second time this week, scientists have reported the discovery of a human antibody that, at least in theory, could lead to development of a vaccine or drug effective against most types of influenza A, including the deadly H5N1 avian flu virus.
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
Editor's note: This is the bibliography to a seven-part series launched October 25, 2007, investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
(CIDRAP News) Antibodies gleaned from four Vietnamese patients who survived H5N1 avian influenza were used successfully to prevent and treat H5N1 infection in mice, suggesting that the same approach might be useful in humans, according to a recent report by an international team of researchers.
(CIDRAP News) A network of clinical researchers stretching from Southeast Asia to the United States is about to begin testing whether doubling the standard dosage of oseltamivir (Tamiflu) will help patients overcome either the often-deadly H5N1 avian influenza or severe seasonal flu.
(CIDRAP News) – California scientists report that their analysis of the medical literature has yielded data on more than 600 molecular components of influenza A viruses that trigger immune responses, findings they hope will spur the search for vaccines offering protection against multiple flu strains.
(CIDRAP News) Scientists say they have developed an inexpensive "gene chip" test that can quickly identify a variety of influenza A viruses, including H5N1, and is less apt to be confused by viral mutations than other tests are.